SCHEMBL22564594

SCHEMBL22564594

C=C(C)C1(C)CCC(C)=CC1c1c(O)cc(CCCCC)c(C(=O)O)c1O

nearest known ligand 0.64

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DAGLA Q9Y4D2 3/20 0.64
NAAA Q02083 1/20 0.64
CNR1 P21554 10/20 0.53
CNR2 P34972 7/20 0.51
LDHA P00338 1/20 0.51
PPARG P37231 1/20 0.51
TRPM8 Q7Z2W7 1/20 0.51
TRPV1 Q8NER1 1/20 0.45
GPR55 Q9Y2T6 1/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24704102 1.00 DAGLA (0.64) DAGLANAAACNR1CNR2LDHA
SCHEMBL24132001 1.00 DAGLA (0.64) DAGLANAAACNR1CNR2LDHA
SCHEMBL24703764 0.93 DAGLA (0.62) DAGLANAAACNR1CNR2LDHA
SCHEMBL24703761 0.93 DAGLA (0.62) DAGLANAAACNR1CNR2LDHA
SCHEMBL24704101 0.84 DAGLA (0.57) DAGLANAAACNR1CNR2LDHA
SCHEMBL24299982 0.84 TRPV1 (0.46) DAGLANAAACNR1CNR2LDHA
SCHEMBL24703680 0.81 CNR2 (0.57) DAGLANAAACNR1CNR2LDHA
SCHEMBL23052897 0.81 CNR2 (0.57) DAGLANAAACNR1CNR2LDHA
SCHEMBL22957097 0.81 CNR2 (0.57) DAGLANAAACNR1CNR2LDHA
SCHEMBL13609362 0.81 CNR2 (0.57) DAGLANAAACNR1CNR2LDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024058552-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES, COMPRISING CANNABINOIDS AS ACTIVE INGREDIENT, AND USES THEREOF 주식회사 네오켄바이오 2024-03-21 WO disclosed
WO-2021195520-A1 BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS GINKGO BIOWORKS, INC. (US) 2021-09-30 WO disclosed
EP-3355873-B1 USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATORY SKIN DISEASES GW PHARMA LTD (GB) 2020-10-21 EP disclosed